文献速递血栓与止血

直接口服抗凝药在抗磷脂综合征中的应用

Use of direct oral anticoagulants in antiphospholipid syndrome.
PubMed 文献 · J Thromb Haemost · 2018-05-13

直接口服抗凝药(DOACs)是华法林等维生素K拮抗剂(VKAs)的替代选择,而VKAs是血栓性抗磷脂综合征(APS)的传统治疗。利伐沙班在抗磷脂综合征(RAPS)随机对照试验以实验室替代指标为主要结局,提示利伐沙班有潜力成为华法林的替代选择,但需进一步研究提供长期疗效和安全性数据后才能广泛推荐。

要点

  • VKAs是血栓性APS的传统治疗,但凝血活酶对狼疮抗凝物敏感性不一,INR可能不能准确反映抗凝强度。
  • RAPS随机对照试验以实验室替代指标为主要结局,提示利伐沙班有潜力成为华法林的替代选择。
  • 需进一步研究提供长期疗效和安全性数据后,利伐沙班才能广泛推荐用于APS。

核心结论

  • RAPS随机对照试验提示利伐沙班有潜力成为需要标准强度抗凝的单次静脉血栓栓塞事件血栓性APS患者的有效且方便的华法林替代选择,但需进一步研究提供长期疗效和安全性数据后才能广泛推荐。

研究设计与样本

  • 基于有限临床试验数据及其他来源信息(包括制造商数据、病例系列或队列研究、专家共识)的综述,涉及RAPS随机对照试验。

主要发现

  • VKAs是血栓性APS治疗和二级血栓预防的传统疗法,但常因凝血活酶对狼疮抗凝物的敏感性不一而存在问题,INR可能不能准确反映抗凝强度或临床有效。
  • RAPS随机对照试验以实验室替代指标为主要结局,提示利伐沙班有潜力成为需要标准强度抗凝的单次静脉血栓栓塞事件血栓性APS患者的有效且方便的华法林替代选择。
  • APS患者临床异质性大,复发血栓风险和抗凝强度受临床表型和风险特征影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 当前DOACs在APS治疗中作用的定义基于有限的临床试验数据及其他来源信息。
  • 需进一步研究,特别是提供更好的长期疗效和安全性数据后,利伐沙班才能广泛推荐。
  • APS患者临床异质性大,复发血栓风险和抗凝强度受临床表型和风险特征影响。
  • 涉及同质血栓性APS人群且抗磷脂抗体状态明确的DOAC试验将有助于优化APS患者亚组的适当治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The direct oral anticoagulants (DOACs) are therapeutic alternatives to warfarin and other vitamin K antagonists (VKAs), and constitute the standard of care for many indications. VKAs constitute the conventional therapy for the treatment and secondary thromboprophylaxis of thrombotic antiphospholipid syndrome (APS), but are often problematic, owing to the variable sensitivity of thromboplastins to lupus anticoagulant. Thus, the International Normalized Ratio may not accurately reflect anticoagulation intensity, or be clinically effective. Definition of the current role of DOACs in the treatment of APS is based on limited clinical trial data and information from other sources, including manufacturers' data, case series or cohort studies, and expert consensus. The Rivaroxaban in Antiphospholipid Syndrome (RAPS) randomized controlled trial (RCT), which had a laboratory surrogate primary outcome measure, suggests that rivaroxaban has the potential to be an effective and convenient alternative to warfarin in thrombotic APS patients with a single venous thromboembolism event requiring standard-intensity anticoagulation. However, further studies, in particular to provide better long-term efficacy and safety data, are needed before it can be widely recommended. APS patients are clinically heterogeneous, with the risk of recurrent thrombosis and the intensity of anticoagulation being influenced by their clinical phenotype and risk profile. DOAC trials involving homogeneous thrombotic APS populations, with the antiphospholipid antibody status well defined, will help to optimize the appropriate treatment in APS patient subgroups. Ongoing and emerging DOAC RCTs should provide further information to guide the use of DOACs in APS patients. Optimal identification of APS patients is a key step in working towards improved therapeutic strategies in these individuals.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Cohen H, Efthymiou M, Isenberg DA, et al. Use of direct oral anticoagulants in antiphospholipid syndrome. J Thromb Haemost. 2018. PMID: 29624847. doi:10.1111/jth.14017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。